Brink Therapeutics is a biotech start-up on a mission to make transformative Cell and Gene Therapies available to all those in need. We focus on the development of best-in-class genome modification enzymes based on site-specific recombinases, highly efficient natural enzymes evolved to drive precise DNA modifications without causing toxic double-strand breaks. They offer a safer, more precise alternative to existing technologies like CRISPR-Cas9, opening up new, more scalable avenues for Cell and Gene Therapy, both ex vivo and in vivo. By harnessing advanced Directed Evolution and natural gene-mining techniques combined with AI for massively accelerated enzyme design, we strive to unlock new possibilities for treating cancers and genetic diseases.